Olmesartan Medoxomilo + Hidroclorotiazida Aurovitas (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomilo + Hidroclorotiazida Aurovitas, is an ARAR presented as a tablet for oral use. It treats hypertension in adult patients, often in combination with a diuretic. GNH USA supplies Olmesartan Medoxomilo + Hidroclorotiazida Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartan Medoxomilo + Hidroclorotiazida Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan medoxil combined with hydrochlorothiazide is used to manage blood pressure through the renin‑angiotensin system and diuretic pathways.

- Hypertension: helps lower systolic and diastolic blood pressure in adults. - Hypertensive urgency: provides additional control when rapid reduction is needed under supervision. - Resistant hypertension: assists when blood pressure remains uncontrolled despite other therapies.

Side effects may vary in frequency and severity.

Common Side Effects: - Dizziness - Headache - Fatigue - Increased urination - Electrolyte imbalance (low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia - Angio‑edema - Liver function abnormalities - Blood cell disorders (e.g., neutropenia).

Patients should be evaluated for cardiovascular and renal status before starting therapy.

- Monitor blood pressure: ensure target levels are achieved without excessive drop. - Assess renal function: adjust dose if creatinine clearance is reduced. - Check electrolytes: watch for sodium and potassium disturbances. - Avoid in pregnancy: drug may harm the fetus. - Caution with elderly: start at lower dose and monitor closely. - Store below 25°C: keep in the original packaging, protect from moisture.

Olmesartan medoxil and hydrochlorothazole may interact with several medicines.

Major Interactions (Avoid): - Potassium‑rich supplements: risk of hyperkalemia. - Aliskiren: combined renin‑angiotensin blockade can increase renal impairment. - NSAIDs: may blunt antihypertensive effect and affect kidney function.

Moderate Interactions (Monitor Closely): - Lithium: increased lithium levels and toxicity risk. - Diuretics other than hydrochlorothiazide: additive electrolyte changes. - ACE inhibitors: may increase risk of angio‑edema. - Antidiabetic drugs: may enhance hypoglycaemic effect. - Antifungal azoles (e.g., ketoconazole): may raise olmesartan levels.